Plasma FGF21 is increased in NASH while FGF19 seem to be downregulated, thus it is of high interest that pharmacological intervention with analogues of the two hormones improves NASH resolution and decrease fibrosis in humans as described below. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.